Fig. 1
From: PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus
PGLYRP2 level increased in SLE patients. (A) Serum level of PGLYRP2 was significantly higher in SLE patients with stable disease (4468.99 ± 457.02 pg/ml), and those with active LN (5152.93 ± 446.13 pg/ml) or NP-SLE (5141.52 ± 579.61 pg/ml), than that healthy volunteers (3938.56 ± 576.07 pg/ml). (B) PGLYRP2 level in PBMCs was significantly higher in SLE patients with active LN or NP-SLE than that of healthy volunteers. (C) Receiver operating characteristic (ROC) curves showed that serum PGLYRP2 was capable of distinguishing SLE patients with active disease from those with stable disease (AUC = 0.841, 95%CI = 0.722–0.960, P = 0.000). *P < 0.05, ** < 0.01, ****P < 0.0001